Oxytocin inhaled - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences

Drug Profile

Oxytocin inhaled - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences

Alternative Names: GR-121619; Heat-stable oxytocin - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Monash Institute of Pharmaceutical Sciences
  • Developer GlaxoSmithKline
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Labour disorders

Most Recent Events

  • 01 Nov 2016 GlaxoSmithKline in collaboration with Monash University initiates enrolment in a phase I trial for Labour disorders in United Kingdom (NCT02999100)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 GlaxoSmithKline completes a phase I trial in Healthy female volunteers in United Kingdom (Inhalation) (NCT02542813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top